Veru Inc. SEC filings VERU
Veru Inc. has 1,000 filings in SEC EDGAR's recent list, going back to May 14, 2007. Its latest annual report, Form 10-K, was filed on Dec 17, 2025 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (other events). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jan 28, 2026 | — |
| DEF 14A | Proxy statement | Jan 28, 2026 | Mar 12, 2026 |
| DEFA14A | Additional proxy material | Jul 15, 2025 | — |
| DEFA14A | Additional proxy material | Jun 10, 2025 | — |
| DEF 14A | Proxy statement | Jun 10, 2025 | Jul 25, 2025 |
| PRE 14A | Preliminary proxy statement | May 9, 2025 | Jul 25, 2025 |
| DEFA14A | Additional proxy material | Jan 28, 2025 | — |
| DEF 14A | Proxy statement | Jan 28, 2025 | Mar 13, 2025 |
| DEFA14A | Additional proxy material | Jun 20, 2024 | — |
| DEFA14A | Additional proxy material | Jun 18, 2024 | — |
| DEFA14A | Additional proxy material | May 9, 2024 | — |
| DEFA14A | Additional proxy material | Apr 1, 2024 | — |
| DEFA14A | Additional proxy material | Mar 22, 2024 | — |
| DEFA14A | Additional proxy material | Jan 26, 2024 | — |
| DEF 14A | Proxy statement | Jan 26, 2024 | Mar 26, 2024 |
| DEFA14A | Additional proxy material | Jun 12, 2023 | — |
| DEF 14A | Proxy statement | Jun 12, 2023 | Jul 24, 2023 |
| PRE 14A | Preliminary proxy statement | May 15, 2023 | Jul 24, 2023 |
| DEFA14A | Additional proxy material | Jan 27, 2023 | — |
| DEF 14A | Proxy statement | Jan 27, 2023 | Mar 28, 2023 |
| DEFA14A | Additional proxy material | Jan 28, 2022 | — |
| DEF 14A | Proxy statement | Jan 28, 2022 | Mar 29, 2022 |
| DEFA14A | Additional proxy material | Jan 28, 2021 | — |
| DEF 14A | Proxy statement | Jan 28, 2021 | Mar 23, 2021 |
| DEFA14A | Additional proxy material | Feb 11, 2020 | — |
| DEFA14A | Additional proxy material | Jan 28, 2020 | — |
| DEF 14A | Proxy statement | Jan 28, 2020 | Mar 24, 2020 |
| DEFA14A | Additional proxy material | Jan 28, 2019 | — |
| DEF 14A | Proxy statement | Jan 28, 2019 | Mar 26, 2019 |
| PRE 14A | Preliminary proxy statement | Dec 14, 2018 | Mar 26, 2019 |
| DEFA14A | Additional proxy material | Jan 26, 2018 | — |
| DEF 14A | Proxy statement | Jan 26, 2018 | Mar 20, 2018 |
| DEFA14A | Additional proxy material | Jul 25, 2017 | — |
| DEFA14A | Additional proxy material | Jul 17, 2017 | — |
| DEFA14A | Additional proxy material | Jul 14, 2017 | — |
| DEF 14A | Proxy statement | Jun 21, 2017 | Jul 28, 2017 |
| PRE 14A | Preliminary proxy statement | May 19, 2017 | May 19, 2017 |
| DEFA14A | Additional proxy material | Jan 27, 2017 | — |
| DEF 14A | Proxy statement | Jan 27, 2017 | Mar 16, 2017 |
| DEFA14A | Additional proxy material | Oct 18, 2016 | — |
| DEFA14A | Additional proxy material | Oct 14, 2016 | — |
| DEFA14A | Additional proxy material | Oct 11, 2016 | — |
| DEFA14A | Additional proxy material | Oct 7, 2016 | — |
| DEFA14A | Additional proxy material | Sep 26, 2016 | — |
| DEFA14A | Additional proxy material | Sep 22, 2016 | — |
| DEFA14A | Additional proxy material | Sep 20, 2016 | — |
| DEFA14A | Additional proxy material | Sep 15, 2016 | — |
| DEFA14A | Additional proxy material | Sep 13, 2016 | — |
| DEFA14A | Additional proxy material | Sep 6, 2016 | — |
| DEFA14A | Additional proxy material | Sep 1, 2016 | — |
| DEFA14A | Additional proxy material | Aug 17, 2016 | — |
| DEFA14A | Additional proxy material | Aug 11, 2016 | — |
| DEFA14A | Additional proxy material | Aug 9, 2016 | — |
| DEFM14A | Filing | Aug 8, 2016 | — |
| DEFA14A | Additional proxy material | Aug 1, 2016 | — |
| DEFA14A | Additional proxy material | Jul 28, 2016 | — |
| DEFA14A | Additional proxy material | Jul 21, 2016 | — |
| DEFA14A | Additional proxy material | Jul 15, 2016 | — |
| DEFA14A | Additional proxy material | Jul 6, 2016 | — |
| DEFA14A | Additional proxy material | Jun 7, 2016 | — |
| DEFA14A | Additional proxy material | Jun 3, 2016 | — |
| DEFA14A | Additional proxy material | May 20, 2016 | — |
| PREM14A | Filing | May 18, 2016 | May 18, 2016 |
| DEFA14A | Additional proxy material | May 18, 2016 | — |
| DEFA14A | Additional proxy material | May 5, 2016 | — |
| DEFA14A | Additional proxy material | May 2, 2016 | — |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEFA14A | Additional proxy material | Apr 15, 2016 | — |
| DEFA14A | Additional proxy material | Apr 13, 2016 | — |
| DEFA14A | Additional proxy material | Apr 12, 2016 | — |
| DEFA14A | Additional proxy material | Apr 7, 2016 | — |
| DEFA14A | Additional proxy material | Apr 6, 2016 | — |
| DEFA14A | Additional proxy material | Apr 6, 2016 | — |
| DEFA14A | Additional proxy material | Jan 26, 2016 | — |
| DEF 14A | Proxy statement | Jan 26, 2016 | Mar 15, 2016 |
| DEFA14A | Additional proxy material | Jan 27, 2015 | — |
| DEF 14A | Proxy statement | Jan 27, 2015 | Mar 19, 2015 |
| DEF 14A | Proxy statement | Jan 28, 2014 | Mar 20, 2014 |
| DEF 14A | Proxy statement | Feb 25, 2013 | Mar 26, 2013 |
| DEF 14A | Proxy statement | Feb 24, 2012 | Mar 22, 2012 |
| DEF 14A | Proxy statement | Feb 28, 2011 | Mar 24, 2011 |
| DEF 14A | Proxy statement | Feb 26, 2010 | Mar 25, 2010 |
| DEF 14A | Proxy statement | Feb 24, 2009 | Apr 2, 2009 |
| DEF 14A | Proxy statement | Feb 20, 2008 | Mar 27, 2008 |
Showing 85 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VERU (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- WI
- Headquarters
- Miami, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 863894
- Former names
- FEMALE HEALTH CO (until Aug 1, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.